Published on 16 Apr 2024 on Zacks via Yahoo Finance
Corcept (CORT) Completes Enrollment in Phase II ALS Study
Corcept Therapeutics Incorporated CORT announced that it has completed enrollment in the phase II DAZALS study, which is evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.
The primary endpoint of this double-blind, placebo-controlled phase II study is to see the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R), a measure of motor impairment and functional deterioration in ALS patients. Meanwhile, overall survival and quality of life remain key secondary endpoints of DAZALS.